Followers | 166 |
Posts | 36223 |
Boards Moderated | 7 |
Alias Born | 10/20/2019 |
![](https://investorshub.advfn.com/uicon/725019.png?cb=1611686644)
Tuesday, June 14, 2022 8:51:18 AM
As an integral part of her role, Ms. Edwards will manage the design and logistical operations of the Company’s multifaceted clinical trials - to include subjects in the US and EU - which support key stages of the FDA submission process for ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). She will also develop and liaise closely with Key Opinion Leaders responsible for carrying out, or contributing to, both the European and US clinical studies and supporting related publications.
Recent MYNZ News
- Micro Cap Bid Up Following FDA Submission Announcement • AllPennyStocks.com • 07/09/2024 01:30:00 PM
- Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test • GlobeNewswire Inc. • 07/09/2024 07:01:00 AM
- Mainz Biomed Provides Half Year 2024 Corporate Update • GlobeNewswire Inc. • 07/02/2024 12:01:00 PM
- Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 • GlobeNewswire Inc. • 06/03/2024 12:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 09:01:03 PM
- Mainz Biomed Reports Results of 2024 Annual General Meeting • GlobeNewswire Inc. • 05/31/2024 09:01:00 PM
- Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting • GlobeNewswire Inc. • 05/28/2024 12:01:00 PM
- Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial • GlobeNewswire Inc. • 05/20/2024 12:01:00 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 05/10/2024 09:20:09 PM
- Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. • GlobeNewswire Inc. • 05/07/2024 12:01:00 PM
- Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic • GlobeNewswire Inc. • 04/25/2024 01:29:00 PM
- Mainz Biomed Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/09/2024 12:01:00 PM
- Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment • GlobeNewswire Inc. • 03/19/2024 12:01:00 PM
- Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options • GlobeNewswire Inc. • 03/18/2024 12:01:00 PM
- Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations • GlobeNewswire Inc. • 03/12/2024 12:01:00 PM
- Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic • GlobeNewswire Inc. • 03/05/2024 01:01:00 PM
- Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community • GlobeNewswire Inc. • 02/27/2024 01:01:00 PM
- Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® • GlobeNewswire Inc. • 02/22/2024 01:01:00 PM
- Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy • GlobeNewswire Inc. • 02/21/2024 01:01:00 PM
- Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany • GlobeNewswire Inc. • 02/06/2024 01:01:00 PM
- Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium • GlobeNewswire Inc. • 01/11/2024 01:01:00 PM
- Mainz Biomed Provides Year-End Corporate Review 2023 • GlobeNewswire Inc. • 01/09/2024 01:01:00 PM
- Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees • GlobeNewswire Inc. • 12/19/2023 01:01:00 PM
- Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland • GlobeNewswire Inc. • 12/12/2023 01:01:00 PM
- Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers • GlobeNewswire Inc. • 12/05/2023 02:01:55 PM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM